Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

Key Inclusion Criteria: * All individuals: * Screening laboratory values within defined thresholds for group * Use of two effective contraception methods if female of childbearing potential or sexually active male * For individuals with moderate hepatic impairment: * Diagnosis of chronic (\> 6 months) hepatic impairment * Score on the Child-Pugh-Turcotte (CPT) scale of 7-9 at screening (Child Pugh Class B). * For individuals with severe hepatic impairment: * Diagnosis of chronic (\> 6 months) hepatic impairment * Score on the CPT scale of 10-15 at screening (Child Pugh Class C) * For individuals with normal hepatic function: * Hepatitis C Virus (HCV) antibody and hepatitis B surface antigen negative Key Exclusion Criteria: * All individuals: * Pregnant or nursing female or male with pregnant female partner * HIV infection * History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment or compliance with the protocol * For individuals with moderate or severe hepatic impairment: * Active HCV infection * Current hepatic encephalopathy * Variceal bleeding in the last 6 months unless banded * Prior placement of a portosystemic shunt * History of hepatorenal or hepatopulmonary syndrome * Spontaneous bacterial peritonitis currently or within the last 6 months * Hospitalization within the last 2 months related to cirrhosis * Confirmed hypotension * Suspicion of hepatocellular carcinoma Note: Other protocol defined Inclusion/Exclusion criteria may apply.